Trial Profile
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2019
Price :
$35
*
At a glance
- Drugs THR 184 (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors Thrasos Therapeutics
- 29 Feb 2016 According to a Thrasos Therapeutics media release, full results of this study will be submitted for presentation at an upcoming scientific conference.
- 29 Feb 2016 Top-line results published in a Thrasos Therapeutics media release.
- 29 Feb 2016 According to a Thrasos Therapeutics media release, status changed from active, no longer recruiting to completed.